GlassScriptPhysician profile
Raymond Lau
NPI 1902005960
$5,796.32
in general payments reported to CMS, 2019-2025
26 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $410 · 2021: $292 · 2022: $445 · 2023: $694 · 2024: $1,679 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,296.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,201.84 | 2019-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $781.49 | 2019-2025 | |
| Esperion Therapeutics, INC. | $649.86 | 2020-2024 | Nexletol, Nexlizet |
| Viiv Healthcare Company | $602.24 | 2025 | Apretude |
| Abbvie INC. | $597.50 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $399.44 | 2021-2023 | Xarelto |
| Intra-Sana Laboratories | $339.54 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Amgen INC. | $245.71 | 2022-2025 | Otezla, Repatha, Krystexxa |
| Gilead Sciences, INC. | $161.59 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Vifor Pharma, INC. | $125.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $104.79 | 2025 | Rexulti |
| Lilly USA, LLC | $71.40 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $66.89 | 2019-2020 | |
| Glaxosmithkline, LLC. | $52.05 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.88 | 2024 | Camzyos |
| Merck Sharp & Dohme LLC | $39.69 | 2019-2020 | |
| Boston Scientific Corporation | $35.17 | 2019 | |
| Sanofi Pasteur INC. | $27.68 | 2019 | |
| Pfizer INC. | $26.65 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $19.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.81 | 2020 | |
| Lifescan, INC. | $17.57 | 2021 | |
| Currax Pharmaceuticals LLC | $16.22 | 2025 | Contrave |
| Antares Pharma, INC. | $14.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.